Inventor · disambiguated record
Paul E. Erdman
Also filed as: ERDMAN PAUL · ERDMAN PAUL E
38 granted patents·20 pending applications·215 citations·filing 2000–2024
97Inventor score
Top patents by PatentIndex Score
58 records- 0196US9701643B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Jul 11, 2017·19 cites·18 claims
- 0295US10144745B2Chimeric compounds targeting proteins, compositions, methods, and uses thereofBIOTHERYX INC·Filed 2017·Granted Dec 4, 2018·15 cites·18 claims
- 0395US10040804B2Compounds targeting proteins, compositions, methods, and uses thereofBIOTHERYX INC·Filed 2017·Granted Aug 7, 2018·17 cites·30 claims
- 0494US10040770B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2017·Granted Aug 7, 2018·7 cites·18 claims
- 0594US9139534B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithBENNETT BRYDON L·Filed 2012·Granted Sep 22, 2015·30 cites·76 claims
- 0693US10266500B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2018·Granted Apr 23, 2019·5 cites·14 claims
- 0793US9938302B2Chimeric compounds targeting proteins, compositions, methods, and uses thereofBIO THERYX INC·Filed 2017·Granted Apr 10, 2018·21 cites·26 claims
- 0892US11325890B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2020·Granted May 10, 2022·2 cites·18 claims
- 0992US10889593B2Compounds targeting proteins, compositions, methods, and uses thereofBIOTHERYX INC·Filed 2019·Granted Jan 12, 2021·4 cites·27 claims
- 1092US10336771B2Compounds targeting proteins, compositions, methods, and uses thereofBIOTHERYX INC·Filed 2018·Granted Jul 2, 2019·8 cites·24 claims
- 1188US10406165B2Compounds targeting proteins, compositions, methods, and uses thereofBIOTHERYX INC·Filed 2018·Granted Sep 10, 2019·6 cites·25 claims
- 1287US10669260B2Compounds targeting proteins, compositions, methods, and uses thereofBIOTHERYX INC·Filed 2017·Granted Jun 2, 2020·3 cites·15 claims
- 1387US8299056B2Aminotriazolopyridines, compositions thereof, and methods of treatment therewithBAHMANYAR SOGOLE·Filed 2009·Granted Oct 30, 2012·22 cites·31 claims
- 1486US10919865B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2019·Granted Feb 16, 2021·3 cites·16 claims
- 1586US10905684B2Aminoamide compoundsBIOTHERYX INC·Filed 2019·Granted Feb 2, 2021·2 cites·29 claims
- 1686US7442699B2Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2005·Granted Oct 28, 2008·10 cites·8 claims
- 1784US11274108B2Colony stimulating factor-1 receptor (CSF-1R) inhibitorsGENZYME CORP·Filed 2016·Granted Mar 15, 2022·2 cites·15 claims
- 1883US11236105B2Bicyclic compounds and methods of useBIOTHERYX INC·Filed 2020·Granted Feb 1, 2022·1 cites·22 claims
- 1983US9428509B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted Aug 30, 2016·6 cites·32 claims
- 2083US9346812B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted May 24, 2016·6 cites·30 claims
- 2183US7122544B2Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2001·Granted Oct 17, 2006·20 cites·20 claims
- 2282US9822098B2Compounds targeting proteins, compositions, methods, and uses thereofBIOTHERYX INC·Filed 2016·Granted Nov 21, 2017·3 cites·22 claims
- 2380US12129237B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2022·Granted Oct 29, 2024·0 cites·6 claims
- 2480US10570147B2Bicyclic compounds and methods of useBIOTHERYX INC·Filed 2018·Granted Feb 25, 2020·2 cites·30 claims
- 2579US12503477B2Colony stimulating factor-1 receptor (CSF-1R) inhibitorsGENZYME CORP·Filed 2024·Granted Dec 23, 2025·0 cites·6 claims
- 2678US10844039B2Substituted isoindolinonesBIOTHERYX INC·Filed 2019·Granted Nov 24, 2020·1 cites·36 claims
- 2774US11345714B2Compounds targeting proteins, compositions, methods, and uses thereofBIOTHERYX INC·Filed 2021·Granted May 31, 2022·0 cites·32 claims
- 2869US2022396588A1Colony stimulating factor-1 receptor (csf-1r) inhibitorsGENZYME CORP·Filed 2022·Application pending·0 cites
- 2967US2022298172A1Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2022·Application pending·0 cites
- 3066US2022153751A1Bifunctional compoundsBIOTHERYX INC·Filed 2022·Application pending·0 cites
- 3164US11400084B2Aminoamide compoundsBIOTHERYX INC·Filed 2021·Granted Aug 2, 2022·0 cites·21 claims
- 3264US11352338B2Substituted isoindolinonesBIOTHERYX INC·Filed 2020·Granted Jun 7, 2022·0 cites·22 claims
- 3364US2022088025A1Fused thiophene compoundsBIOTHERYX INC·Filed 2021·Application pending·0 cites
- 3464US2024190883A1Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2023·Application pending·0 cites
- 3563US12419962B2Quinazolines, pharmaceutical compositions, and therapeutic applicationsBIOTHERYX INC·Filed 2023·Granted Sep 23, 2025·0 cites·23 claims
- 3663US11191769B2Fused thiophene compoundsBIOTHERYX INC·Filed 2019·Granted Dec 7, 2021·0 cites·39 claims
- 3763US2025186434A1Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2023·Application pending·0 cites
- 3862US11236103B2Bifunctional compoundsBIOTHERYX INC·Filed 2019·Granted Feb 1, 2022·0 cites·33 claims
- 3962US10562917B2Chimeric compounds targeting proteins, compositions, methods, and uses thereofBIOTHERYX INC·Filed 2018·Granted Feb 18, 2020·0 cites·22 claims
- 4061US2024174643A1Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIO THERYX INC·Filed 2023·Application pending·0 cites
- 4161US2019276474A1Chimeric compounds targeting proteins, compositions, methods, and uses thereofBIOTHERYX INC·Filed 2018·Application pending·0 cites
- 4261US2023339904A1Isoindolinones, pharmaceutical compositions, and therapeutic applicationsBIO THERYX INC·Filed 2023·Application pending·0 cites
- 4359US11345712B2Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2020·Granted May 31, 2022·0 cites·51 claims
- 4459US2024368121A1Estrogen receptor degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2022·Application pending·0 cites
- 4556US10857155B2Compounds targeting proteins, compositions, methods, and uses thereofBIOTHERYX INC·Filed 2019·Granted Dec 8, 2020·0 cites·9 claims
- 4656US2024124418A1Pde4 degraders, pharmaceutical compositions, and therapeutic applicationsBIOTHERYX INC·Filed 2021·Application pending·0 cites
- 4756US2024190885A1Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2022·Application pending·0 cites
- 4854US2023201144A1Biarylsulfonamides and pharmaceutical compositions thereof, and their use for treating fibrotic lung diseaseNOVOMEDIX LLC·Filed 2021·Application pending·0 cites
- 4954US2024197888A1Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2022·Application pending·0 cites
- 5054US2024025863A1Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Paul E. Erdman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →